Point of Care Testing market size is expected to reach USD 57.08 Billion by 2027

Point of Care Testing market size is expected to reach USD 57.08 Billion by 2027, according to a new report by Emergen Research. Increasing government initiatives to promote the use of Point of Care Testing products and the rise in the geriatric population are driving the demand of the market.
Besides, the emergence of next-gen POC testing devices such as smartphone based devices and cost-effective wearable glucose meters are also contributing to the growing sales of the market. Increasing research and development for the production of technologically advanced, cost-effective, and user-friendly product is augmenting the demand for the industry.
To be updated, the report is furnished with the latest impact of the currently unfolding coronavirus pandemic on the Point of Care Testing industry. The pandemic began in late 2019 and hit the world in early 2020, disrupting the normal lives and affecting every segment of the world.
Covid-19 is a significant contributor to the increase in the POC testing product's revenue as a massive number of Covid-19 screenings are being performed in the affected areas.
The report gives a comprehensive report offering beneficial data about the competitive landscape of the Point of Care Testing market and covers key details of the key companies along with their revenue contribution, financial standing, profit margins, strategic alliances such as mergers and acquisitions, and other key elements.
Get a sample of the report @ https://www.emergenresearch.com/request-sample/101
The following companies have been profiled in the report:
• Abbott Laboratories
• Chembio Diagnostics
• Siemens
• Roche Diagnostics
• Danaher Corporation
• Johnson & Johnson
• Qiagen
• Becton
• Dickinson and Company
• Nova Biomedical
• Quidel Corporation
• others.
Emergen Research has segmented the global Point of Care Testing Market on the basis of Product, End-User, Mode of Purchase, and region:
• Product Outlook (Revenue, USD Billion; 2017-2027)
o Infectious Disease Testing Products
o Glucose Monitoring Products
o Pregnancy and fertility Testing Products
o Cardio-metabolic Monitoring Products
o Hematology Testing Products
o Cholesterol Testing Products
o Tumor/Cancer Marker Testing Products
o Others
• End-User Outlook (Revenue, USD Billion; 2017-2027)
o Clinical Laboratories
o Home care Settings
o Hospitals
o Others
• Mode of Purchase Outlook (Revenue, USD Billion; 2017-2027)
o Over-the-counter (OTC) Products
o Prescription Based Products
To read more about the report, visit @ https://www.emergenresearch.com/industry-report/point-of-care-testing-market
Some Key Highlights From the Report
• The Glucose Monitoring Products segment dominated the market with a share of 28.5% in 2019 due to the growing occurrence of diabetes and an increase in the number of glucose monitoring products. Also, the increasing prevalence of cancer globally contributes to the growth of the Tumor/Cancer Marker Testing Product.
• The Home care Settings is expected to register the highest CAGR of 10.9% over the forecast period as the patients prefer home care settings.
Point of Care Testing Segmentation based on Key Geographical Regions:
• North America (U.S., Canada)
• Europe (U.K., Italy, Germany, France, Rest of EU)
• Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
• Latin America (Chile, Brazil, Argentina, Rest of Latin America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)
Asia-Pacific is expected to register the highest CAGR over the forecast period due to the increasing prevalence of infectious diseases and diabetes.
Request customization of the report @ https://www.emergenresearch.com/industry-report/point-of-care-testing-market